Wilson Sonsini Goodrich & Rosati is advising Arcellx on the transaction. Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD) announced that they have...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Arcellx on the deal. Arcellx, a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arcellx on the deal. Arcellx, a privately held clinical-stage biopharmaceutical company, announced that it raised $115 million in a Series...
You must be a Standard 1 Year member to access this content.
